A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma
about
The NF-κB Pathway and Cancer Stem CellsMan's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?Protein-Protein Interactions Mediated by Helical Tertiary Structure Motifs.Protein engineering of the N-terminus of NEMO: structure stabilization and rescue of IKKβ binding.NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy.Targeting NF-κB in glioblastoma: A therapeutic approachCanine lymphoma: a review.Enhancing the Cell Permeability and Metabolic Stability of Peptidyl Drugs by Reversible Bicyclization.Tumor suppression via inhibition of SWI/SNF complex-dependent NF-κB activationA model of the onset of the senescence associated secretory phenotype after DNA damage induced senescence.Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation.Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ InhibitorsCell-Permeable Bicyclic Peptidyl Inhibitors against NEMO-IκB Kinase Interaction Directly from a Combinatorial Library
P2860
Q26750605-D2C1EF9B-F31C-409B-A9F9-1E0959A7AA81Q27027137-FB1C934B-F721-43D3-A3AB-C8EE7F13E8CAQ30378305-449D46F4-3248-434B-82E6-40BFD59B7F9AQ34463911-99521C67-EADA-4E8B-AD8A-324628C87F53Q35190356-5430983A-9A2A-44DD-A9BE-3028ABBCE61CQ36514117-B56E0E2A-8DD9-41A8-90A4-F94E846B2FE4Q38765145-7810DD69-A270-4F03-AE8F-ADFD8FE3E2B6Q40402014-C723507C-7E1F-4E03-A838-3B02DA22B335Q41718087-86471C8D-34C1-4ED7-BE0D-68E9726F535BQ47137519-1AB8D2A5-3E00-40D1-810F-7C7D39D481ECQ54976552-FA9B8EB5-325E-4507-BA1F-80D071927C01Q55058976-3E71AA52-C9AF-494E-9464-4C4B89057801Q57167736-2F50D7B6-53B2-42B2-878B-FE778D042B29Q58698975-89E676E7-7A50-49E0-BC3D-B884079CAAAC
P2860
A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@ast
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@en
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@nl
type
label
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@ast
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@en
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@nl
prefLabel
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@ast
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@en
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@nl
P2093
P2860
P3181
P1433
P1476
A phase I clinical trial of sy ...... diffuse large B-cell lymphoma
@en
P2093
Albert S Baldwin
Anita Gaurnier-Hausser
Erika Krick
Georges Habineza Ndikuyeze
Kathleen J Propert
Nicola J Mason
Patrick Flood
Reema Patel
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0095404
P407
P577
2014-01-01T00:00:00Z